Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Calcium handling properties and arrhythmia vulnerability of cardiomyocytes from dystrophin-deficient mdx mice.

Cell calcium·2026

Same author

A high-toughness, rare-earth-free magnesium alloy with excellent biocompatibility profile: Integrated in vitro and in vivo characterization.

Materials today. Bio·2026

Same author

Exploring Perivascular Adipose Tissue Responses to Bioresorbable Thermoplastic Polyurethane Vascular Grafts.

Biomaterials research·2026

Same author

Transcription-independent induction of rapid-onset senescence is integral to healing.

Nature cell biology·2026

Same author

Post-resuscitation left ventricular dysfunction in a rat model of ventricular fibrillation and extracorporeal cardiopulmonary resuscitation.

Scientific reports·2026

Same author

Cardiovascular, limb, and kidney effects of SGLT2 inhibitors in patients with peripheral artery disease: a systematic review and meta-analysis of randomized controlled trial data.

Cardiovascular diabetology·2026

Search research articles

Related Experiment Video

Updated: Jul 3, 2026

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

Evolving cell-based therapies for heart failure patients.

Bruno K Podesser¹, Michael Bauer, Ronglih Liao

¹Cardiac Muscle Research Laboratory, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, NRB 431, Boston, MA 02115, USA.

Current Treatment Options in Cardiovascular Medicine

|July 24, 2008

Summary

This summary is machine-generated.

Cell-based therapies show promise for treating heart failure (HF) by regenerating lost cardiac cells. While trials demonstrate safety, outcomes are mixed, and optimal cell types and delivery methods require further research.

More Related Videos

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Related Experiment Videos

Last Updated: Jul 3, 2026

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Area of Science:

Regenerative Medicine
Cardiovascular Diseases
Cell Therapy

Background:

Heart failure (HF) incidence is rising globally, with high mortality despite advances in treatment.
Cardiac cell loss significantly contributes to HF progression.
Existing therapies offer limited regeneration potential for damaged heart tissue.

Purpose of the Study:

To review the current status of cell-based therapies for cardiovascular diseases (CVD).
To focus on the application and challenges of cell therapy in treating heart failure.
To identify key areas for future research in cardiac cell regeneration.

Main Methods:

Review of existing clinical trials and animal studies on cell-based therapies for CVD.
Analysis of patient populations, cell types used (e.g., skeletal myoblasts, bone marrow cells), and delivery methods.
Evaluation of reported outcomes and safety profiles of cell therapies in heart failure trials.

Main Results:

Cell-based therapy trials for CVD have yielded mixed results, with some showing benefits and others no improvement.
All trials to date have demonstrated a reasonable safety profile within the study period.
Limited trials have specifically focused on patients with congestive heart failure.

Conclusions:

Cell-based therapies hold promise for repairing or regenerating cardiac cells lost in heart failure.
Critical issues like cell type, dosage, timing, delivery, and mechanisms of action need further investigation.
Continued research is essential to optimize cell therapy for effective heart failure treatment.